Thoroughbred Financial Services’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$445K Sell
2,756
-1,446
-34% -$241K 0.02% 461
2026
Q2
$796K Sell
4,202
-30
-0.7% -$5.64K 0.04% 341
2026
Q1
$834K Sell
4,232
-6
-0.1% -$1.16K 0.05% 316
2025
Q4
$779K Buy
4,238
+158
+4% +$27.7K 0.05% 316
2025
Q3
$626K Sell
4,080
-201
-5% -$30.4K 0.04% 348
2025
Q2
$598K Sell
4,281
-8,666
-67% -$1.21M 0.04% 340
2025
Q1
$1.9M Buy
12,947
+127
+1% +$18.4K 0.12% 178
2024
Q4
$1.68M Sell
12,820
-1,270
-9% -$178K 0.1% 185
2024
Q3
$2.2M Sell
14,090
-32
-0.2% -$5.17K 0.14% 139
2024
Q2
$2.2M Buy
14,122
+8,347
+145% +$1.26M 0.15% 137
2024
Q1
$782K Sell
5,775
-11,790
-67% -$1.56M 0.08% 236
2023
Q4
$2.36M Buy
17,565
+1,106
+7% +$144K 0.19% 110
2023
Q3
$2.23M Buy
16,459
+7,714
+88% +$1.05M 0.22% 96
2023
Q2
$1.25M Buy
8,745
+620
+8% +$91.2K 0.16% 140
2023
Q1
$1.13M Buy
8,125
+1,566
+24% +$211K 0.17% 145
2022
Q4
$889K Buy
+6,559
New +$823K 0.15% 157

Other funds holding AZN

Thoroughbred Financial Services's AZN Position: Q3 2026 in Review

Thoroughbred Financial Services reduced its AstraZeneca (AZN) stake by 34% in Q3 2026, selling an estimated $241K and leaving 2,756 shares worth $445K. The position accounts for 0.02% of the portfolio, ranked #461.

Thoroughbred Financial Services first reported a position in AZN in Q4 2022 and has held it in 16 quarters since. The position peaked at $2.36M in Q4 2023. 1,222 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Thoroughbred Financial Services held 2,756 shares of AstraZeneca worth $445K as of Q3 2026.
  • Thoroughbred Financial Services sold 1,446 AstraZeneca shares in Q3 2026, an estimated $241K.
  • AstraZeneca made up 0.02% of Thoroughbred Financial Services's portfolio in Q3 2026, its #461 holding.
  • Thoroughbred Financial Services first reported a position in AstraZeneca in Q4 2022 and has held it in 16 quarters since.
  • Thoroughbred Financial Services's AstraZeneca position peaked at $2.36M in Q4 2023.
  • 1,222 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Thoroughbred Financial Services's 13F filing for Q3 2026, filed 9 Nov 2026.